The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment

The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment

Blog Article

Sodium taurocholate cotransporting polypeptide (NTCP) acts as a cellular receptor for the hepatitis B virus infection of host hepatocytes.Previously, many studies confirmed that the NTCP p.Ser267Phe variant was a protective factor against HBV-related disease progression.

We therefore designed this study to investigate whether the NTCP p.Ser267Phe variant exerts an additive anti-HBV effect in chronic hepatitis B (CHB) patients on mainstream NAs treatment.After sigma kappa graphics propensity score matching (PSM), a total of 136 CHB patients were included, among whom 68 were heterozygous carriers and 68 were wild-type controls.

Proportions of primary nonresponse, partial virological response, virological breakthrough and hepatitis B reactivation and the HBV DNA clearance rate at each time point were compared using the chi-square test.Kaplan-Meier analysis and matched t-tests were also performed to estimate the speed of viral clearance and serum advantage household spot & crevice spray HBV DNA reduction, respectively.The proportion of primary nonresponse was significantly lower in heterozygous carriers than in wild-type controls (p < 0.

001), especially in patients using entecavir (p = 0.013).Specifically, heterozygous carriers achieved HBV DNA clearance faster than wild-type controls (log-rank p = 0.

0198).HBV DNA levels were reduced more in heterozygous carriers after 12 weeks (p < 0.001) and 24 weeks (p = 0.

006) of treatment, especially among patients using ETV.Here, our study demonstrated that heterozygous mutations in rs2296651 enhanced the antiviral response of first-line NAs and helped to explore the possibility of combining NAs and NTCP blockers for a better anti-HBV effect.